We have updated our Terms of Use.
Please read our new Privacy Statement before continuing.

Marketing triumph?

23 October 2003 By Robert Cyran

The AngloSwedish drugs company increased Q3 sales despite $2bn in lost sales to generics. But Nexium, the franchise drug, looks like a shaky base upon which to build earnings.

This content is for Subscribers only


Email a friend

Please complete the form below.

Required fields *


(Separate multiple email addresses with commas)